iTeos Therapeutics, Inc.

ITOS

US46565G1040

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
10.6 ^USD	+0.28%		+2.61%	-3.20%

Mar. 13	Top Premarket Decliners	MT
Mar. 12	JPMorgan Adjusts Price Target on iTeos Therapeutics to $27 From $29, Maintains Overweight Rating	MT

ITeos Therapeutics, Inc.(NasdaqGM:ITOS) dropped from Russell 2500 Growth Index

June 25, 2021 at 12:00 am EDT

iTeos Therapeutics, Inc.(NasdaqGM:ITOS) dropped from Russell 2500 Growth Index

Latest news about iTeos Therapeutics, Inc.

Top Premarket Decliners	Mar. 13	MT
JPMorgan Adjusts Price Target on iTeos Therapeutics to $27 From $29, Maintains Overweight Rating	Mar. 12	MT
Wedbush Adjusts iTeos Therapeutics Price Target to $18 From $25, Maintains Outperform Rating	Mar. 06	MT
ITeos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
ITeos Therapeutics, Inc. Appoints Jill DeSimone to its Board of Directors, Effective March 7, 2024	Mar. 06	CI
Transcript : ITeos Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:00 PM	Jan. 10
Iteos Therapeutics, Inc. Announces Business Updates and Strategic Priorities for 2024	Jan. 08	CI
ITeos Therapeutics, Inc.(NasdaqGM:ITOS) dropped from S&P Biotechnology Select Industry Index	Dec. 18	CI
Iteos Therapeutics, Inc. Announces Board Changes	Dec. 07	CI
JPMorgan Cuts Price Target on iTeos Therapeutics to $29 From $32, Maintains Overweight Rating	Nov. 13	MT
ITeos Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
ITeos Therapeutics, Inc.(NasdaqGM:ITOS) dropped from S&P 1000	23-10-18	CI
ITeos Therapeutics, Inc.(NasdaqGM:ITOS) dropped from S&P 600 Health Care	23-10-18	CI
ITeos Therapeutics, Inc.(NasdaqGM:ITOS) dropped from S&P Composite 1500	23-10-18	CI
ITeos Therapeutics, Inc.(NasdaqGM:ITOS) dropped from S&P 600	23-10-18	CI
NCR Atleos to Join S&P SmallCap 600 Index, Replacing iTeos Therapeutics	23-10-12	MT
NCR Atleos to Join S&P SmallCap 600 Index, Replacing iTeos Therapeutics	23-10-12	MT
Sector Update: Health Care Stocks Rising Late Afternoon	23-08-23	MT
Sector Update: Health Care Stocks Gaining in Afternoon Trading	23-08-23	MT
Top Midday Gainers	23-08-23	MT
Arcus Biosciences, iTeos Therapeutics Shares Rise After Roche's Positive Lung Cancer Interim Results	23-08-23	MT
Top Premarket Gainers	23-08-23	MT
ITeos Therapeutics Shares Surge More Than 21% in Premarket Activity Wednesday	23-08-23	MT
HC Wainwright Adjusts Price Target on iTeos Therapeutics to $44 From $54, Maintains Buy Rating	23-08-09	MT
ITeos Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI

Chart iTeos Therapeutics, Inc.

Duration

Period

More charts

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its advanced program is inupadenant, also known as EOS-850, a next-generation adenosine 2A receptor (A2AR) antagonist tailored to overcome the specific adenosine-mediated immunosuppression found in the tumor microenvironment. Its program to initiate clinical trials is EOS-984, a potentially first-in-class small molecule focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1 (ENT1), a dominant transporter of adenosine on lymphocytes involved in T cell metabolism.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for iTeos Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.6 USD

Average target price

34.4 USD

Spread / Average Target

+224.53%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ITEOS THERAPEUTICS, INC.	-3.20%	381M
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	103B
REGENERON PHARMACEUTICALS, INC.	+1.41%	95.71B
ARGENX SE	+0.79%	22.02B
BIONTECH SE	-17.84%	20.9B
GENMAB A/S	-9.23%	17.85B
WUXI APPTEC CO., LTD.	-42.83%	16.21B
BEIGENE, LTD.	-17.63%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.86B
SAREPTA THERAPEUTICS, INC.	+32.11%	12.04B

Bio Therapeutic Drugs